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Platelet-activating factor (PAF)' is a mediator of inflammation with a wide
range of biological activities (see reference 1 for review). PAF was initially
recognized as a product of IgE-sensitized rabbit basophils (2) and was identified
with 1-0-alkyl-2-sn-glyceryl-3-phosphorylcholine (3-5). It was subsequently
shown that PAF is synthesized after appropriate stimulation by mono-
cytes/macrophages (6-9), polymorphonuclear neutrophils (7, 10, 11), platelets
(12) and endothelial cells (13-15) . PAF induces aggregation and degranulation
of platelets (2, 16), stimulates contraction of smooth muscle (17), promotes
chemotaxis and granule secretion of neutrophils (18-19) and monocytes (20),
increases vascular permeability, and alters the vascular tone (21).
It was recently suggested that PAF is a mediator of endotoxic shock (22-24)
on the basis of the following observations: (a) PAF is produced during endotoxic
shock and experimental sepsis by Gram-negative bacteria (23-25); (b) infusion
of experimental animals with PAF results in hypotension, decrease in cardiac
output, and hypovolemic shock (26-28); (c) three PAF receptor antagonists
(CV3988, kadsurenone, and SRI 63072) inhibit or reverse endotoxin-induced
hypotension and, in this way, prolong the survival of rats (22, 23, 29).
Tumor necrosis factor/cachectin (TNF) is a mediator of endotoxic shock (30).
Because TNF administration to experimental animals reproduces several aspects
of PAF infusion (30), it seems possible that PAF is synthesized in response to
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TNF . The aim of the present study was to establish whether TNF stimulates
synthesis of PAF in cultures of different primary and tumor cell lines. The results
obtained show that TNF-treated rat peritoneal macrophages and polymorpho-
nuclear neutrophils (PMN), and human vascular endothelial cells synthesize and
release PAF.
Materials and Methods
Cell Cultures.
￿
Peritoneal cells were obtained from Lewis rats of 250-300 g according
to Bloom et al. (31). The peritoneum was washed with RPMI 1640 medium buffered with
5 mM Pipes containing 0 .25% of lipid-free BSA. The cells were washed twice with this
medium by 5 min centrifugation at 200 g, counted in a hemocytometer, and resuspended
in MEM at 107 cells/ml. The cells were then plated in 3.5-cm-diam plastic dishes and
incubated for 60 min at 37°C. Nonadherent cells were removed by three washes with
MEM containing 0.25% BSA; 90-95% of the adherent cells were characterized as
macrophages on the basis of positive staining for nonspecific esterase performed on
formalin-fixed cells with a-naphtol-AS-D-chloroacetate, specific esterase staining (32), and
by phagocytosis of complement-activated zymosan particles (0.2 mg/ml) or of latex beads
after incubation for 30 min at 37'C. Rat PMN were cultured as described (7). Endothelial
cells were isolated from the human umbilical cord vein, cultured in Iscove's medium
supplemented with 15% fetal calf serum (FCS), and characterized as previously described
(13). Primary cultures were plated in 3.5-cm-diam plastic dishes, washed, and refed with
the same medium every 2 d and 12 h before PAT synthesis assays. These cells were used
when confluent after 4-7 d ofculture. Human melanoma SK-MEL-109 cells were cultured
in F12 and MEM (1 :1) with 8% FCS. HeLa cells and human osteosarcoma (HOS) cells
were cultured in Dulbecco's medium with 10% FCS. Human foreskin fibroblasts were
cultured in F12 medium with 10% FCS and grown to confluency before treatment with
TNF.
Synthesis and Release ofPAF.
￿
For each assay, 2.5 X 105 or 106 cells were incubated at
37 °C with either human or murine recombinant TNF (hTNF or mTNF), obtained
respectively from Dr. Tatsuro Nishihara ofthe Suntory Institute for Biomedical Research,
Osaka, Japan, and from Dr. Walter Fiers, University of Ghent, Ghent, Belgium. In some
experiments, macrophages were incubated with the calcium ionophore A231ß7 and with
complement-activated zymosan C (33), or preincubated for 10 min at 37 ° C with: acetyl-
coenzyme A (acetyl-CoA); 2-lyso-PAF(Bachem Feinchemikalien, Bubendorf, Switzerland);
EDTA; p-bromodiphenacylbromide (PBDB); L-1-tosylamide-2-phenylethyl chloromethyl
ketone (TPCK); and N-acetyl-n, L-phenylalanine-g-naphthyl ester (APNE). To label PAF,
macrophages were preincubated for 2 h with 15 uCi of [5H]acetyl-CoA (1 Ci/mmol;
Amersham Corp., Arlington Heights, IL) or with 2 .5,Ci ['H]2-lyso-PAF in 2 ml of MEM
containing 0 .25% BSA. This preincubation was previously found to yield maximal
incorporation of the labeled precursors into PAF (34). After washing, the cells were
stimulated with mTNF and the reactions were stopped by adding EDTA to 20 mM. The
supernatant was removed and adherent cells were harvested with a rubber policeman in
1 ml of methanol. PAF was extracted from supernatant and cells according to Bligh and
Dyer (35), with formic acid added to lower the pH of the aqueous phase to 3.0 (36). In
parallel experiments, cell viability was monitored by Trypan blue exclusion and ranged
between 89 and 92% after 4 h incubation with different doses of TNF, 95-99% after 1
h incubation with complement-activated zymosan, and 85-90% after 1 h incubation with
A231ß7 .
PAF Purification.
￿
The supernatants and the methanol fraction obtained from cells
were extracted with a 1 :1 :0.9 (vol/vol/vol) mixture of chloroform, methanol, and water
or medium, and the chloroform-rich phase was retained (37). To measure the overall
recovery of PAF, 10 nCi of [5H]PAF was added to the cells or supernatants and extracted
as described above. The extracted lipids were analyzed by thin layer chromatography
(TLC) on silica gel plates 60 F254 (E. Merck, Darmstadt, Federal Republic of Germany)
developed with 65 :35 :6 (vol/vol/vol) chloroform, methanol, and water(37). 1-cm2 sections1392 TUMOR NECROSIS FACTOR AND PLATELET-ACTIVATING FACTOR
of the plates were scraped into glass tubes and the lipids were extracted three times for
30 min with 2 ml of 1 :2:0.8 (vol/vol/vol) chloroform, methanol, and water. The silica was
removed by centrifugation and the supernatant was adjusted to and extracted with 1 :1 :0.9
(vol/vol/vol) chloroform, methanol, and water. The chloroform phase was then removed
and dried. The dried material was resuspended for quantitation and characterization of
PAF in Tris-buffered Tyrode's solution (2.6 mM KCI, I mM MgC12, 1 .37 M NaCl, 6 mM
CaCl2, 0.1 % sucrose, and I mM Tris buffer, pH 7 .4) containing 0.25% BSA (fraction V;
Pentex Biochemicals, Kankakee, IL).
In studies with labeled precursors of PAF, the lipidextracts were chromatographed on
60 F254 TLC plates with 50:25:8.4 (vol/vol/vol/vol) chloroform, methanol, acetic acid,
and water(34); 0.5 cm2 sections were scraped, and radioactivity was counted after addition
ofscintillation liquid. Commercially available synthetic PAF and 2-lyso-PAF, L-2-phospha-
tidylcholine (PC) and sphingomyelin from bovine brain, and L-2-lyso-PC from bovine liver
(Sigma Chemical Co., St. Louis, MO) were used as standards. The recovery of ['H]PAF
after extraction and purification was 96-98% .
PAF Assay.
￿
After extraction and purification, PAF was detected by aggregation of
washed rabbit platelets prepared as described (38), using an aggregometer. For PAF assay,
5 x 107 platelets were stirred at 37 ° C in 0.3 ml of Tris-buffered Tyrode's solution
supplemented with 0 .25% gelatin (Difco Laboratories, Detroit, MI), 0 .01 mM indometh-
acin to inhibit cyclooxygenase, 312.5 mg/liter of creatine phosphate and 152 .5 mg/liter
of creatine phosphokinase to convert ADP into ATP. In this way, both arachidonic acid-
and ADP-dependent platelet aggregation were blocked. PAF concentration was calculated
from a calibration curve with 10 u1 of various solutions containing synthetic PAF added
to rabbit platelets at a final concentration of 1-15 ng/ml. A linear correlation between
platelet aggregation and added PAF was observed in a concentration range of 1-10
ng/ml. PAF was quantitated after extraction and purification by TLC (37), and its
concentration was calculated on the linear portion of the calibration curve from at least
three dilutions of the same sample. This method allowed to quantitate (in nanograms per
milliliter) biologically active material of standard PAF.
Characterization of PAF.
￿
Biologically active material extracted from cells and super-
natant in different experiments was characterized by comparison with PAF obtained from
sensitized rabbit basophils (37) and with synthetic PAF by the following criteria (39): (a)
induction of platelet aggregation by a pathway independent from both ADP- and arachi-
donic acid/thromboxane A2-mediated pathways; (b) specificity of platelet aggregation
inferred from the inhibitory effect of 5,M SR163072 (29) and CV3988 (40), two different
PAF receptor antagonists; (c) physicochemical characteristics such as inactivation by strong
bases and phospholipase A2, but resistance to phospholipase A, (41), acids, weak bases,
and 5 min heating in boiling water. The methods used were previously described in detail
(39).
Results
The experiments shown in Fig. 1 established that rat peritoneal macrophages
adherent to plastic dishes release PAF in response to TNF. The macrophages
were incubated for 1 h with 20 ng/ml of mTNF and PAF was assayed after
purification from cells and medium as described in Materials and Methods. The
macrophages produced PAF in amounts comparable to those obtained during
phagocytosis of complement-activated zymosan C, and ^-75% of maximal synthe-
sis obtained with the calcium ionophore A23187 (Fig. 1). The level of cell-
associated PAF was approximately equal to that in the medium, suggesting that
TNF was a potent inducer of both PAF synthesis and release. The material
extracted from cellsand medium had biologic and physicochemical characteristics
identical to those of synthetic PAF and of PAF released from IgE-sensitized
rabbit basophils. It induced platelet aggregation in an ADP- and arachidonicá
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FIGURE 1 . Synthesis and release of PAF by
ratperitoneal macrophages treated for I hwith
1 gg/ml of A23187, 0.2 mg/ml of zymosan C,
20 ng/ml ofmTNF or untreated. 106cellswere
used foreach experiment. Cell-associated PAF,
shaded columns; supernatant PAF, blank col-
umns. In this and the following figures, PAF
concentration is referred to 1 ml of cell culture
medium and to the corresponding cell aliquot
to allow comparison of the amount of PAF
released with that remaining cell associated.
Vertical bars indicate the standard deviationof
themean of different experiments (n = 3). The
assay of PAF was carried out in duplicate for
A2307
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each experiment.
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acid-independent way, which was specifically inhibited by the PAF receptor
antagonists SR163072 and CV3988 (29, 40). PAF activity was destroyed after
base-catalyzed methanolysis (0-1% residual activity) or after treatment with
phospholipase A2 (0-3% residual activity), indicating the presence of an ester
linkage at sn-2 (13, 37, 41-43). Treatment with phospholipase A1 did not inhibit
PAF activity, suggesting the presence of an ether bond at sn-1 (13, 41). The
PAF activity was resistant to treatment with acids or weak bases (21, 37). After
base-catalyzed methanolysis or digestion with phospholipase A2, treatment with
acetic anhydride restored 88.7 ± 7% (n = 3) of the biologic activity. The PAF
obtained from macrophages had the same Rf (0.21) in TLC as synthetic PAF,
using as solvent chloroform/methanol/water (65:35 :6). No PAF activity was
detected in any other TLC fraction. The Rf of PAF changed to 0 .10 by using in
TLC a solvent with different polarity (chloroform/methanol/water; 65 :35:4),
indicating that PAF extracted from macrophages is a polar lipid.
Evidence that PAF was synthesized de novo by mTNF-treated rat peritoneal
macrophages was obtained by following the incorporation of radioactive precur-
sors. TLC analysis of the lipid fraction extracted 1 h after addition of mTNF
from macrophages preincubated with [sH]acetyl-CoA showed one main peak of
radioactivity that comigrated with synthetic PAF ; this peak was absent from the
lipid fraction of untreated macrophages (Fig. 2A). Another experiment showed
that exogenous 2-lyso-PAF could be a substrate for PAF synthesis. TLC analysis
of the lipid fraction of macrophages preincubated with [3H]2-lyso-PAF plus 0 .1
mM unlabelled acetyl-CoA and then treated with mTNF showed three peaks of
radioactivity (Fig. 2B). The first peak comigrated with 2-lyso-PAF, the second
peak with PAF, and the third peak with PC. In the lipid fraction of untreated
cells the PAF peak was absent, indicating that [sH]2-lyso-PAF was only converted
into other phospholipids comigrating with PC. It should be pointed out that, in
these experiments, efficient conversion of 2-lyso-PAF into PAF required the
addition of acetyl-CoA, since only a small peak of radioactivity comigrated with
PAF when the lipid fraction of cells preincubated with ['H]2-lyso-PAF alone and
treated with mTNF was analyzed by TLC (data not shown).
Time Course and Dose-Response of PAF Synthesis.
￿
The following experiments
measured the time course of PAF synthesis and release into the supernatant by
macrophages treated with 20 ng/ml of mTNF (Fig. 3). After 30 min PAF was
mainly cell associated, whereas after 1 h it was present in equal amounts in cells1394 TUMOR NECROSIS FACTOR AND PLATELET-ACTIVATING FACTOR
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FIGURE 2. Representative TLC analysis of
PAF synthesized by ratperitoneal macrophages
stimulated for I h with 20 ng/ml of mTNF
after 2 h preincubation with 15 uCi/ml o£
[sH]acetyl-CoA (A) or with 0.1 mM unlabelled
acetyl-CoA and 2 ACi/ml ['H]2-lyso-PAF (B).
The lipids were extracted from cellsandsuper-
natant (35) and analyzed by TLC using as sol-
vent chloroform/methanol/acetic acid/water
(50:25:8:4). The plates were divided into 30
sections of 0.5 cm each and counted as de-
scribed in Materials and Methods. Thepattern
obtained with TNF-stimulated cells (0) and
control unstimulated cells (A) is shown. In par-
allel experiments, labeled PAF, PC, and 2-lyso-
PAF were chromatographed as standards; the
position of these compounds is indicated.
Threeexperiments were performed with simi-
lar results on cell-associated and supernatant
lipids.
FIGURE 3.
￿
Time course of PAF synthesis and release by rat
peritoneal macrophages stimulated with 20 ng/ml of mTNF.
Cell-associated PAF (0) and PAF released in the supernatant
(A)areshown; 10' cellswere used for each time point.
and supernatant. Cell-associated PAF decreased afterwards, whereas that in the
supernatant increased sharply after 1 h but declined slightly after 4 h (Fig. 3).
This indicated that maximal synthesis of PAF occurred within 1 h of TNF
addition, and that PAF was gradually released into the supernatant from 1 to 4
h. Some PAF was also inactivated during this time, since its total amount (cell
associated plus supernatant) decreased. The synthesis of PAF and its release by
macrophages in response to different doses of mTNF or hTNF was also measured
(Fig. 4). PAF was extracted from cells and supernatant 1 h after TNF addition.
The amount of cell-associated PAF was approximately equal to that found in the
supernatant at all TNF concentrations tested. Significant PAF synthesis was
detected with 1 ng/ml of mTNF and nearly maximal synthesis with 10 ng/ml.
Fivefold greater concentrations of hTNF were required to obtain a similar
response.
The Effect ofPrecursors and Enzyme Inhibitors on PAF Synthesis.
￿
The effect of
precursors of PAF and of inhibitors of cyclooxygenase or phospholipase A2 was20
10
É
ç
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1
￿
5
￿
10 25 50 100
ng/m1 TNF
TABLE I
Effect ofPAF Precursors andEnzyme Inhibitors on the Synthesis ofPAFby
RatPeritoneal Macrophages
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FIGURE 4.
￿
Dose response of PAF synthesis and release by rat
peritoneal macrophages stimulated for 1 h with mTNF (A) or
hTNF (B). The cell-associated PAF (ie) and that released into
the supernatant (A) by 106 cells treated with different concen-
trations of TNFare shown.
For each experiment, 106 ratperitoneal macrophages were preincubated for 10
min with thecompounds indicatedand then incubated for 1 h with 20 ng/ml of
mTNF. Cell-associated PAF and that released into the culture medium were
measured as described in Materials and Methods. Cell viability was between 85
and 92% in experiments with different inhibitors. The mean ± SD of different
experiments (n = 3) is indicated.
investigated in the experiments shown in Table I. Acetyl-CoA stimulated in a
dose-dependent manner the synthesis and release of PAF by peritoneal macro-
phages treated for 1 h with 20 ng/ml of mTNF. It should be pointed out that
no PAF activity was recovered from the supernatant of untreated macrophages
in control experiments (n = 8) carried out in the absence of acetyl-CoA. In
contrast, minimal amounts of PAF (1.2 ± 0.8 ng/ml) were extracted from
macrophages treated with 0.1 mM acetyl-CoA. When these cells were preincu-
Compound added Concen-
tration
PAF
Cell associated Released
kM Mg/ml
Acetyl-CoA 0 15 .5 ± 3.3 15.8 ± 3.7
1 15.2 ± 3.3 16.2 ± 3.3
10 20.5±3 .5 22.2±1 .8
50 23.1±2.5 23.7±2.6
100 24.4±2.4 26.4±3.3
2-Lyso-PAF 1 15.8 ± 2.9 16.8 ± 3.3
2-Lyso-PAF + acetyl-CoA 1+100 27.8±1 .7 28.5±3.4
APNE 100 5.3±2.5 2.4±0.6
TPCK 10 0.9 ± 0.9 <0.1
EDTA 100 0.7 ± 0.6 <0.1
Indomethacin 10 16.3 ± 1.5 15.3 ± 1.4
PBDB 1 4.7 ± 1.5 3.5 ± 1.41396 TUMOR NECROSIS FACTOR AND PLATELET-ACTIVATING FACTOR
FIGURE 5. Time course (A) and dose re-
sponse (B) of PAF synthesis and release by
humanendothelial cellsstimulated with hTNF.
The cell-associated PAF (0) and that released
in the supernatant (A) after treatment with 10
ng/ml of hTNF or after 4 h incubation with
different concentrations of hTNF is shown; 2.5
X 105 cells were used for each time point and
hTNF concentration. Thevertical bars indicate
thestandard deviationof themean of different
experiments (n = 5).
bated with 2-lyso-PAF before mTNF addition, no significant increase in PAF
production was observed (Table 1). However, addition of both 2-lyso-PAF and
0.1 mM acetyl-CoA increased significantly the synthesis and release of PAF. In
the absence of mTNF, these compounds increased the level of cell-associated
PAF to 2.2 ± 0.6 ng/ml, but did not cause PAF release into the medium (data
not shown).
Two inhibitors of serine proteases that block the cytocidal activity of TNF in
human and murine cells (44) reduced both synthesis and release of PAF (Table
1). The effect of the reversible inhibitor APNE, which is a substrate of proteases
(44), was less pronounced than that of TPCK, an alkylating agent that is an
irreversible inhibitor of proteases (45). TPCK is, on a molar basis, the most
effective antagonist of the cytocidal activity of TNF (44). This inhibitor abolished
the release of PAF into the medium. A similar effect was obtained with the
cation chelator EDTA (Table 1) and with ethylene-bis-(oxyethylenenitrilo)-tetra-
cetic acid, a chelator with high specificity for Ca
2+ (data not shown), suggesting
that synthesis and release of PAF may require Ca
2+ entry into TNF-treated cells.
The inhibitor of cyclooxygenase indomethacin had no effect on PAF synthesis
(Table 1). In contrast, the inhibitor of phospholipase A2 PBDB drastically reduced
synthesis and release of PAF. These findings suggest that PAF is produced upon
TNF-mediated activation of phospholipase A2.
Production ofPAF by Human Vascular Endothelial Cells and Rat PMN.
￿
Cultures
of human endothelial cells obtained from the umbilical vein were treated for
different times and with different concentrations of hTNF. Significant PAF
synthesis was observed after 2 h of treatment, and reached its maximum after 4
h, declining sharply afterwards (Fig. 5A). Most of the PAF synthesized was cell
associated, since only ^-20% was found in the supernatant fraction. The dose-
response of PAF synthesis showed nearly maximal synthesis, with 10 ng/ml of
hTNF and significant synthesis with 1-5 ng/ml (Fig. 5B). Only ^-20% of the
PAF synthesized was found in the supernatant fraction at all concentrations of
hTNF tested. We also assayed synthesis and release of PAF in rat PMN treated
for 1 h with 20 ng/ml of mTNF: 5.7 ± 1 .7 ng of PAF were found associated
with 106 PMN, and 3 ± 1 .1 ng were released per milliliter of medium. In
contrast, no detectable amounts of PAF were recovered after 1-4 h of treatment
with 10 ng/ml of hTNF from human foreskin fibroblasts and tumor cells such
as SK-MEL-109 melanoma, HOS osteosarcoma, and HeLa cells, or from their
culture media (data not shown) . It appears from these results that synthesis and
release of PAF are a specialized cell response to TNF. The reasons for theCAMUSSI ET AL.
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different efficiency of PAF release between macrophages and endothelial cells
are presently unknown.
Discussion
TNF was initially detected in the serum of endotoxin-treated animals as the
mediator of the necrosis of some transplantable tumors in mice (46). It was
subsequently reported that TNF is cytostatic or cytotoxic for certain tumor cells
(47). However, several lines of evidence indicate that this is not the only biologic
activity of TNF. This factor can stimulate fibroblast proliferation (48, 49), is
pyrogenic (50), affects lipid metabolism (51), and modulates several functions of
endothelial cells (52, 53). Furthermore, recent reports indicate that TNF is a
mediator of inflammatory reactions. TNF is chemotactic for monocytes and
PMN (54), stimulates phagocytosis (55), adherence to endothelium (52), and
superoxide production by these cells (56, 57), and induces procoagulant activity
in cultured human vascular endothelial cells (58) . Furthermore, data from
experimental animals suggest that TNF production plays a primary role in
endotoxin shock (59).
A variety of cells that play a role in inflammation have been shown to produce
PAF. This factor may be synthesized and released, after appropriate stimulation,
from cells of the monocyte/macrophage series (6-9), PMN (7, 10, 11), platelets
(12), and endothelial cells (13-15). Therefore, PAF may be involved in a variety
of immunopathological reactions triggered by different cellular effectors. In
addition to its role in acute inflammatory reactions, PAF may be a mediator of
shock when it is released intravascularly in massive amounts within a short period
of time (23-27, 37). The present study shows that, after stimulation with TNF,
rat peritoneal macrophages, human endothelial cells, and rat PMN synthesize
and release PAF.
Appropriate stimuli are necessary to synthesize and release PAF (1, 60). The
calcium ionophore A23187 (6, 33) and the phagocytosis of zymosan (61, 62) or
of immunocomplexes (9) triggers PAF production from monocytes/macro-
phages. The present study shows that the amount of PAF synthesized by TNF-
treated rat peritoneal macrophages is comparable to that produced in response
to phagocytic stimuli. The response to TNF is rapid, since already at 30 min
considerable amounts of PAF are detected in these cells (Fig. 3). The subsequent
decrease of cell-associated PAF in macrophages continuously incubated with
mTNF indicates that its synthesis is a transient response. This can be either a
consequence of downregulation of TNF receptors or of other regulatory mech-
anisms that limit the synthesis of PAF.
Previous studies on a variety of inflammatory cells (8, 13, 63-65), including
zymosan-stimulated macrophages (33), show that PAF is synthesized by two
enzymatic steps: (a) hydrolysis of 2-lyso-PAF by phospholipase A2; and (b)
acetylation of 2-lyso-PAF at position 2 by an acetyl transferase. The first step
requires Ca2' and is inhibited by PBDB (8). The second step is detected by the
incorporation of acetate into PAF by cells incubated with labelled acetyl-CoA (8,
13, 33, 66-68). The biosynthesis of PAF by TNF-stimulated macrophages
involves these two metabolic steps (Fig. 2). The requirement for Cat+, suggested
by the effect of EDTA, and the inhibitory effect of PBDB (Table I) indicates1398 TUMOR NECROSIS FACTOR AND PLATELET-ACTIVATING FACTOR
that phospholipase A2 is involved in 2-lyso-PAF hydrolysis from membrane lipids.
Addition of this compound to TNF-stimulated macrophages does not result in
increased PAF synthesis, whereas acetyl-CoA stimulates PAF synthesis. These
results are in agreement with previous findings (33), which suggest that the
limiting step for PAF biosynthesis is the concentration of activated acetate
available as acetyl-CoA.
The reduced synthesis of PAF observed in the presence of the protease
inhibitors APNE and TPCK suggests that some proteolytic activity is required
for TNF stimulation of PAF synthesis. These compounds protect human and
murine cells incubated with theinhibitor ofprotein synthesis cycloheximide from
the cytocidal activity of TNF (44). It seems therefore possible that this activity
and the synthesis of PAF are elicited through some common step in response to
the signalling of TNF-receptor complexes. Phospholipase A2 activity is thought
to be regulated in vivo by potent inhibitory membrane-associated proteins
designated calpactins or lipocortins (69). Synthesis of PAF may possibly require
some proteolytic cleavage of these proteins to activate phospholipase A2.
Identical amounts of PAF are synthesized by rat peritoneal macrophages in
response to optimal concentrations of either mTNF or hTNF (Fig. 4). However,
mTNF stimulates these macrophages at lower concentrations than hTNF. This
finding may be explained by the species-specificity of TNF. By measuring binding
of radiolabelled mTNF and hTNF to homologous and heterologous receptors
of murine and human cells, Smith et al . (70) have shown that mTNF binds with
almost equal affinity to both cell types, whereas hTNF binds with higher affinity
to human cells than to murine cells. This difference in binding to receptors is
reflected by a correspondingly lower cytostatic activity of hTNF on murine L
cells than on human HeLa cells (70). In the present experiments carried out on
rat cells, mTNF appears to be more effective than hTNF. Therefore, it seems
likely that TNF receptors on rat cells bind mTNF with greater affinity than
hTNF. This concept is supported by the finding that maximal PAF synthesis by
human endothelial cells is obtained with hTNF concentrations similar to those
that induce maximal response in rat peritoneal macrophages with mTNF, namely
10 ng/ml (Figs. 4A and 5B). This TNF concentration (0 .6 nM) results in
occupancy of a large fraction of cellular receptors, based on a Kd at 4°C of 2 x
10-' ° for the hTNF and mTNF receptors (70).
The synthesis of PAF in response to TNF appears to be a specialized response
of cells involved in inflammation . Large amounts of PAF are synthesized by
macrophages and endothelial cells, but macrophages appear to release PAF
rapidly, whereas 80% of the PAF synthesized remains associated with endothelial
cells (Fig. 5). The time course of PAF synthesis is also slower for endothelial cells
than for macrophages. However, the endothelial cells synthesize PAF for a few
hours, in contrast to macrophages, which show a transient synthesis. The obser-
vation that in a continuous incubation with TNF endothelial cells respond
differently from macrophages supports the hypothesis that PAF synthesis is
regulated by specific mechanisms rather than by downregulation of TNF recep-
tors due to receptor-mediated endocytosis. These findings have to be confirmed
with other macrophage and endothelial cell systems, but they suggest that
regulatory networks control the duration of PAF synthesis andrelease in responseCAMUSSI ET AL.
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to TNF. The possibility that PAF itself could promote TNF synthesis was tested
in rat peritoneal macrophages. Treatment of these cells with 5-50 ng/ml of PAF
for 1-4 h did not result in appreciable release of mTNF into the culture medium
(our unpublished observations). This finding suggests that TNF and PAF pro-
duction are not interrelated.
The presence of TNF in the serum of patients with meningococcal meningitis
and/or septicemia has recently been reported (71). TNF was detected in 10 of
11 patients who died, but in only 8 of 68 survivors (71) . Clinical signs of severe
meningococcal disease are leukopenia, thrombocytopenia, and hypotension .
These symptoms may be caused by release of PAF mediated by the TNF in
serum. It seems likely that PAF release may play a significant role in both local
and systemic inflammatory responses to TNF production. Further studies are
necessary to establish the relevance of TNF-mediated PAF synthesis in different
immunopathologic conditions.
Summary
Murine tumor necrosis factor (mTNF) stimulates production of platelet-acti-
vating factor (PAF) by cultured rat peritoneal macrophages in amounts compa-
rable to those formed during treatment with the calcium ionophore A23187 or
phagocytosis of zymosan . The cell-associated PAF that was released into the
medium was identical to synthetic PAF, as determined with physicochemical,
chromatographic, and enzymatic assays. Furthermore, de novo synthesis of PAF
by macrophages was demonstrated by the incorporation of radioactive precursors
such as [sH]acetyl-coenzyme A or [sH]2-lyso-PAF . Macrophages incubated with
mTNF for 4 h synthesized PAF only during the first h of treatment. At this
time, the amount of cell-associated PAF was approximately equal to that released
into the medium. The cell-associated PAF decreased afterwards, whereas that in
the medium did not correspondingly increase, suggesting that some PAF was
being degraded. The response of rat macrophages to different doses of mTNF
and human TNF (hTNF) was examined. Maximal synthesis of PAF was obtained
with 10 ng/ml of mTNF and 50 ng/ml of hTNF. This finding may be explained
by a lower affinity of hTNF for TNF receptors of rat cells. The hTNF stimulated
production of PAF by human vascular endothelial cells cultured from the
umbilical cord vein. The time course of PAF synthesis was slower than that
observed with macrophages, with maximal production between 4 and 6 h of
treatment. Optimal synthesis of PAF was obtained with 10 ng/ml of hTNF . Only
20-30% of the PAF synthesized by endothelial cells was released into the
medium, even after several hours of incubation . Synthesis of PAF in response to
TNF was also detected in rat polymorphonuclear neutrophils, but not in human
tumor cells and dermal fibroblasts. Therefore, production of PAF is a specialized
response that is transient in macrophages continuously treated with TNF, and
that appears to be controlled by unidentified regulatory mechanisms.
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